Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population

Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population

Background Adalimumab (ADA), certolizumab pegol (CER), etanercept (ETA), guselkumab (GUS), ixekizumab (IXE), secukinumab (SEC), and ustekinumab (UST) are biologics approved for the treatment of psoriasis (PsO) and psoriatic arthritis (PsA). We examined adherence and persistence among PsO patients wi...

Full description

Bibliographic Details
Main Authors: Chang Xu, Amanda Teeple, Bingcao Wu, Timothy Fitzgerald, Steven R. Feldman
Format: Article
Language:English
Published: Taylor & Francis Group 2022-05-01
Series:Journal of Dermatological Treatment
Subjects:
adherence
biologics
persistence
psoriasis
psoriatic arthritis
Online Access:http://dx.doi.org/10.1080/09546634.2021.1950600

Internet

http://dx.doi.org/10.1080/09546634.2021.1950600

Similar Items